# Beneficial effects of intermittent intravenous saline infusion in dysautonomic patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: a case-series

**Authors:** Per Sjögren, Helena Huhmar, Bo C. Bertilson, Björn Bragée, Olli Polo

PMC · DOI: 10.3389/fneur.2025.1601599 · Frontiers in Neurology · 2025-07-21

## TL;DR

This study suggests that periodic saline infusions may improve symptoms and quality of life in ME/CFS patients with dysautonomia.

## Contribution

It is the first case-series to report significant improvements in ME/CFS patients using intermittent intravenous saline.

## Key findings

- Significant improvements in symptom scores, quality-of-life, and POTS-related symptoms after saline infusions.
- Ability-to-work also improved significantly following treatment.
- Patients showed consistent positive responses to volume loading over 9 weeks.

## Abstract

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating condition with no single, uniformly effective pharmacologic therapy. Dysautonomic features like orthostatic intolerance and postural tachycardia syndrome are common features in ME/CFS, severely affecting the patient’s quality-of-life. Intermittent saline infusion may reduce symptoms associated with dysautonomia, but this has not been tested scientifically in patients with ME/CFS.

In this case-series, 22 patients with ME/CFS and signs of dysautonomia and/or hypovolemia were treated every third week over 9 weeks with intravenous saline (9 mg/mL NaCl), using standard aseptic technique. Symptoms were monitored throughout the treatment regime, and a follow-up evaluation was conducted.

At treatment start, patients were predominantly female (95%), at mean age 46 ± 10 years, and with a mean body hydration percentage of 48 ± 6. Self-reported health status revealed an overall symptom score of 47 ± 13 on a 0–96 scale, a median POTS score of 64 (IQR 16) on a 0–120 scale, and poor measures of quality-of-life (median 25 IQR 25, on a 0–100 scale) and ability-to-work (median 0, IQR 26, on a 0–100 scale). Following 9 weeks of intermittent saline infusion (mean volume 1,600 ± 360 mL), self-reported composite symptom score, quality-of-life and POTS-related symptoms improved significantly (all p < 0.001), as did ability-to-work (p < 0.05).

Our data derived from a non-controlled case-series indicate health benefits from volume loading with intermittent infusion of saline among patients with ME/CFS, which may stimulate further studies on various forms of intravenous volume loading to patients with ME/CFS and dysautonomia.

## Linked entities

- **Chemicals:** NaCl (PubChem CID 5234)

## Full-text entities

- **Genes:** AVP (arginine vasopressin) [NCBI Gene 551] {aka ADH, ARVP, AVP-NPII, AVRP, VP}
- **Diseases:** hypotension (MESH:D007022), preload failure (MESH:D051437), OI (MESH:D054971), migraine (MESH:D008881), urinary incontinence (MESH:D014549), POTS (MESH:D054972), joint pain (MESH:D018771), PEM (MESH:D000092202), palpitation (MESH:D006331), stroke (MESH:D020521), orthostatic hypotension (MESH:D007024), hypermobility (MESH:C536196), morning stiffness (MESH:D048968), body ache (MESH:D010146), numbness (MESH:D006987), Hypovolemia (MESH:D020896), dizziness (MESH:D004244), weight gain (MESH:D015430), brain fog (MESH:D005222), coordination difficulties (MESH:D001259), flu-like symptoms (MESH:D007251), illness (MESH:D002908), tender lymph nodes (MESH:D000072717), drop in blood pressure (MESH:D006973), memory difficulties (MESH:D008569), fatigue (MESH:D005221), dysautonomia (MESH:D054969), headache (MESH:D006261), sleep disturbance (MESH:D012893), polyuria (MESH:D011141), joint hypermobility (MESH:D007593), Chronic Fatigue Syndrome (MESH:D015673), sore throat (MESH:D010612), Dysautonomic syndromes (MESH:D012791), attention deficits (MESH:D001289)
- **Chemicals:** cortisol (MESH:D006854), -980MA (-), NaCl (MESH:D012965), glucose (MESH:D005947), potassium (MESH:D011188), sodium (MESH:D012964)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12318745/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12318745/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12318745/full.md

---
Source: https://tomesphere.com/paper/PMC12318745